Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 401-411 , May 2008

Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies

  • Bluma Linkowski Faintuch

      Affiliations

    • Radiopharmacy Center, Institute of Energetic and Nuclear Research, Sao Paulo, SP 05508-000, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55 11 38169252; fax: +55 11 38120253.
    • ,
  • Rodrigo Teodoro

      Affiliations

    • Radiopharmacy Center, Institute of Energetic and Nuclear Research, Sao Paulo, SP 05508-000, Brazil
    • ,
  • Adriano Duatti

      Affiliations

    • Laboratory of Nuclear Medicine, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, 44100, Italy
    • ,
  • Emiko Muramoto

      Affiliations

    • Radiopharmacy Center, Institute of Energetic and Nuclear Research, Sao Paulo, SP 05508-000, Brazil
    • ,
  • Salomao Faintuch

      Affiliations

    • Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    • ,
  • Charles J. Smith

      Affiliations

    • Department of Radiology, Missouri University Research Reactor, and Radiopharmaceutical Sciences Institute, University of Missouri-Columbia, The Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA

Received 22 July 2007 ,Revised 17 February 2008 ,Accepted 28 February 2008.

References 

  1. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem. 2000;7:971–994
  2. Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians bombesina and alytes. Experientia. 1971;27:166–169
  3. Nagalla SR, Barry BJ, Falick AM, Gibson BW, Tatkir JE, Dong JZ, et al. There are three distinct forms of bombesin. Identification of [Leu13]bombesin, [Phe13]bombesin, and [Ser3, Arg10, Phe13] bombesin in the frog Bombina orientalis. J Biol Chem. 1996;271:7731–7737
  4. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003;30:861–868
  5. Smith CJ, Wolkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol. 2005;32:733–740
  6. Faintuch BL, Santos RLSR, Souza ALFM, Hoffman TJ, Greeley M, Smith CJ. 99mTc-HYNIC-bombesin (7-14)NH2: Radiochemical evaluation with co-ligands EDDA (EDDA=ethylenediamine-N,N′-diacetic acid), tricine, and nicotinic acid. Synth React Inorg Met-Org Nano-Met Chem. 2005;35:43–51
  7. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.. Ann Oncol Adv Access. 2007;published March 9 on-line
  8. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004;24:357–397
  9. Garayoa EG, Ruegg D, Blauenstein P, Zwimpfer M, Kahn IU, Maes V, et al. Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol. 2007;34:17–28
  10. Hoffman TJ, Quinn TP, Volkert WA. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl Med Biol. 2001;28:527–539
  11. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med. 2005;46:823–830
  12. Banerjee S, Pillai MRA, Ramammorthy N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med. 2001;31:260–277
  13. Blok D, Feitsma HIJ, Kooy YMC, Welling MM, Ossndorp F, Vermeij P, et al. New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides. Nucl Med Biol. 2004;31:815
  14. Van de Wiele C, Dumont F, Broecke RV, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualization of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–1699
  15. Van de Wiele C, Dumont F, Rudy A, Dierckx RA, Peers SH, Thornback J, et al. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722–1727
  16. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med. 2003;30:247–258
  17. Karra SR, Schibli R, Gali H, Katti KV, Hoffman TJ, Higginbotham C, et al. 99mTc labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiaphosphine-based bifunctional chelating agent. Bioconjug Chem. 1999;10:254–260
  18. Baldas J, Bonnyman J. Substitution reactions of 99mTcNCl4-, a new route to a new class of 99mTc-radiopharmaceuticals. Int J Appl Radiat Isot. 1985;36:133
  19. Pasqualini R, Comazzi V, Bellande E, Duatti A, Marchi A. A new efficient method for the preparation of 99mTc-radiopharmaceuticals containing the Tc≡N multiple bond, Int. Appl Radiat Isot. 1992;43:1329
  20. Bolzati C, Mahmood A, Malago E, Uccelli L, Boschi A, Jones AG, et al The [99mTc(N)(PNP)]+2 metal fragment: a technetium-nitrido synthon for use with biologically active molecules. The N-(2-methoxyphenyl)piperazil-cysteine analogues as examples. Bioconjug Chem. 2003;14:1231
  21. Zhang J, Wang X, Li CY. Synthesis and biodistribution of a new 99mTc nitrido complex for cerebral imaging. Nucl Med Biol. 2002;29:665
  22. Zinn KR, Smith CA, Wu Q, Kirkman RL, Mountz JM, Buchsbaum DJ, et al. Imaging adenoviral-mediated gene transfer of gastrin releasing peptide receptor (GRPr) using a Tc-99m-labeled bombesin (BBN) analogue. J Nucl Med. 1998;39:224P;Abstract 994
  23. www.cancer.org – accessed April 30, 2007.
  24. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152–1159
  25. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235
  26. La bella R, Garayoa EG, Langer M, Blauenstein P, Beck-Sickinger AG, Schubiger PA. In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol. 2002;29:553–560
  27. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318–326
  28. Kunstler JU, Veerendra B, Figueroa SD, Sieckman GL, Rold TL, Hoffman TJ, et al. Organometallic 99mTc(III)′4 + 1′ bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem. 2007;18:1651–1661
  29. Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman TJ. Radiochemical investigations of 99mTc-N3S-X-BBN[7-14]NH2: an in vitro/in vivo structure-activity relationship study where X) 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem. 2003;14:93–102

PII: S0969-8051(08)00067-X

doi: 10.1016/j.nucmedbio.2008.02.005

Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 401-411 , May 2008

Article Tools

* Image Usage & Resolution